World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3267)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

111

WORD

HTML

2016

Figures (1-1)

186

Tables (1-1)

254

Sum=2591

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

140

Download

412

Sum=552

Aug 26, 2023 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Khedr A, Hennawi HA, Khan MK, Eissa A, Mir M, Rauf I, Nitesh J, Surani S, Khan SA. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports. World J Clin Cases 2023; 11(24): 5700-5709 [PMID: 37727728 DOI: 10.12998/wjcc.v11.i24.5700]
URL:	https://www.wjgnet.com/2307-8960/full/v11/i24/5700.htm

Number	Citing Articles
1	Medine Cumhur Cure, Erkan Cure. Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?. Current Pharmaceutical Design 2024; 30(15): 1149 doi: 10.2174/0113816128300162240322075423
2	André J Scheen. Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective. The Lancet Diabetes & Endocrinology 2024; 12(10): 685 doi: 10.1016/S2213-8587(24)00230-4